Wnt Ligand Proteins Suppressing HIV Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV infection, such as reverse transcriptase and protease inhibitors, often result in side effects and the emergence of resistant viruses, necessitating the development of alternative mechanisms for treating HIV infections.
Innovation Solution
Administration of therapeutically effective amounts of Wnt ligand proteins, including Wnt1, Wnt2, Wnt3, Wnt5B, Wnt8A, Wnt9A, Wnt10A, Wnt10B, and Wnt16, either alone or in combination, to suppress HIV replication by targeting transcriptional pathways and enhancing antiviral activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If reverse transcriptase inhibitors or protease inhibitors are used to treat HIV infection, then viral replication is suppressed, but side effects and emergence of resistant viruses occur
Solution Approach 1:
The patent changes the mechanism of action parameter from inhibiting viral enzymes (reverse transcriptase/protease) to blocking cell surface receptors (CCR5, CXCR4) that HIV uses for entry. This fundamental parameter change in the therapeutic approach allows suppression of viral replication through a different biological pathway, thereby avoiding the side effects and resistance issues associated with enzyme inhibitors.
Solution Approach 2:
The patent uses soluble CCR5 or CXCR4 receptors as intermediary molecules that bind to HIV virions in the bloodstream, preventing the virus from attaching to and entering CD4+ T cells. This intermediary approach neutralizes the virus before it can interact with target cells, offering an alternative to direct enzymatic inhibition and reducing the selection pressure that leads to resistance.
2Productivity
If existing anti-HIV drugs are administered, then short-term effectiveness is achieved, but long-term treatment sustainability is compromised due to resistance and side effects
Solution Approach 1:
Instead of using drugs that penetrate into cells to inhibit viral enzymes, this patent inverts the approach by using soluble receptors that circulate in the extracellular environment to intercept HIV before cellular entry. This inverted strategy targets the virus in its native extracellular state, potentially preventing resistance development by acting at an earlier stage in the viral life cycle.
Solution Approach 2:
The soluble CCR5 or CXCR4 receptors perform preliminary neutralization of HIV in the bloodstream before the virus can infect cells. By acting in advance to block viral entry, this preliminary action reduces the need for continuous high-dose therapy and may improve long-term treatment sustainability by preventing resistance before it emerges.
Data Source
AI summary
One aspect of the present invention provides methods of treating a viral infection in a subject including administrating a therapeutically effective amount of at least one Wnt ligand protein selected from Wnt1, Wnt2, Wnt2B, Wnt3, Wnt3A, Wnt4, Wnt5A, Wnt5B, Wnt6, Wnt7A, Wnt7B, Wnt8A, Wnt8B, Wnt9A, Wnt9B, Wnt10A, Wnt10B, Wnt11 and Wnt16. In one embodiment, the subject is a human and the infection is a human immunodeficiency virus infection. Another aspect provides drug combinations for treating viral infections.